Literature DB >> 7609092

Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice.

W Chen1, H Kawano, R Men, D Clark, C J Lai.   

Abstract

There are four dengue virus serotypes (DEN1 to -4), each of which causes major epidemics in tropical or subtropical areas. The current strategy for dengue virus immunization favors the use of a tetravalent vaccine preparation. We have previously employed full-length DEN4 cDNA to construct a viable intertypic dengue virus type 1 or type 2 chimera that contained the C-PreM-E or only the PreM-E genes of DEN1 or DEN2 substituting for the corresponding genes of DEN4. This success implied that it might be possible to create mutants of all four dengue virus serotypes for evaluation as candidate vaccines. In this study, we constructed DEN3-DEN4 chimeras that contained DEN3 C-PreM-E genes and expressed DEN3 antigenic specificity. Unlike our previous successes in cloning DEN1 or DEN2 chimeric cDNA, we were not able to clone the DEN3 C-PreM-E genes directly in the 5' intermediate vector or in the full-length chimeric DEN3-DEN4 plasmid in Escherichia coli. Nevertheless, a full-length DNA template of DEN3-DEN4 that could be used for transcription of infections RNAs was prepared by in vitro ligation. Progeny virus recovered from RNA-transfected C6/36 mosquito cells exhibited DEN3 antigenic specificity as determined by a reaction with monoclonal antibodies. Gel electrophoresis of virus-infected cell lysates yielded the predicted viral protein pattern, i.e., DEN3 C, PreM, and E and DEN4 nonstructural proteins. Two amino acid substitutions, Thr-435-->Leu and Glu-406-->Lys, which are analogous to mutations that, respectively, confer mouse neurovirulence on DEN4 and DEN2, were introduced into DEN3 E. A mutant chimera containing the Thr-435-->Leu substitution, which ablates the potential glycosylation site sequence, produced an E protein identical in size to that of wild-type DEN3 E, indicating that the glycosylation site is normally not used. Intracerebral inoculation of suckling mice revealed that the mutant chimera containing the Glu-406-->Lys substitution was neurovirulent, whereas its wild-type counterpart or parent DEN3 was not.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7609092      PMCID: PMC189343          DOI: 10.1128/JVI.69.8.5186-5190.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Cloning full-length dengue type 4 viral DNA sequences: analysis of genes coding for structural proteins.

Authors:  B Zhao; E Mackow; A Buckler-White; L Markoff; R M Chanock; C J Lai; Y Makino
Journal:  Virology       Date:  1986-11       Impact factor: 3.616

2.  Studies on the glycosylation of flavivirus E proteins and the role of carbohydrate in antigenic structure.

Authors:  G Winkler; F X Heinz; C Kunz
Journal:  Virology       Date:  1987-08       Impact factor: 3.616

3.  Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation.

Authors:  C M Rice; A Grakoui; R Galler; T J Chambers
Journal:  New Biol       Date:  1989-12

4.  Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus.

Authors:  C J Lai; B T Zhao; H Hori; M Bray
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

5.  Synthesis of proteins and glycoproteins in dengue type 2 virus-infected vero and Aedes albopictus cells.

Authors:  G W Smith; P J Wright
Journal:  J Gen Virol       Date:  1985-03       Impact factor: 3.891

6.  The envelope glycoproteins of dengue 1 and dengue 2 viruses grown in mosquito cells differ in their utilization of potential glycosylation sites.

Authors:  A J Johnson; F Guirakhoo; J T Roehrig
Journal:  Virology       Date:  1994-09       Impact factor: 3.616

7.  Dengue in Greece in 1927 and 1928 and the pathogenesis of dengue hemorrhagic fever: new data and a different conclusion.

Authors:  L Rosen
Journal:  Am J Trop Med Hyg       Date:  1986-05       Impact factor: 2.345

8.  Infectious Japanese encephalitis virus RNA can be synthesized from in vitro-ligated cDNA templates.

Authors:  H Sumiyoshi; C H Hoke; D W Trent
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

9.  Nucleotide sequence of the virulent SA-14 strain of Japanese encephalitis virus and its attenuated vaccine derivative, SA-14-14-2.

Authors:  S Nitayaphan; J A Grant; G J Chang; D W Trent
Journal:  Virology       Date:  1990-08       Impact factor: 3.616

10.  PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE.

Authors:  A B Sabin; R W Schlesinger
Journal:  Science       Date:  1945-06-22       Impact factor: 47.728

View more
  19 in total

1.  A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease.

Authors:  Vanessa V Sarathy; Mellodee White; Li Li; Summer R Gorder; Richard B Pyles; Gerald A Campbell; Gregg N Milligan; Nigel Bourne; Alan D T Barrett
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.

Authors:  S Butrapet; C Y Huang; D J Pierro; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.

Authors:  C Y Huang; S Butrapet; D J Pierro; G J Chang; A R Hunt; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.

Authors:  Alexander J McAuley; Maricela Torres; Jessica A Plante; Claire Y-H Huang; Dennis A Bente; David W C Beasley
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

5.  Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge.

Authors:  M Bray; R Men; C J Lai
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

Review 6.  Mouse models of dengue virus infection for vaccine testing.

Authors:  Vanessa V Sarathy; Gregg N Milligan; Nigel Bourne; Alan D T Barrett
Journal:  Vaccine       Date:  2015-10-23       Impact factor: 3.641

7.  Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates.

Authors:  S S Whitehead; M G Hill; C Y Firestone; M St Claire; W R Elkins; B R Murphy; P L Collins
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

8.  Successful propagation of flavivirus infectious cDNAs by a novel method to reduce the cryptic bacterial promoter activity of virus genomes.

Authors:  Szu-Yuan Pu; Ren-Huang Wu; Chi-Chen Yang; Tzu-Ming Jao; Ming-Han Tsai; Jing-Chyi Wang; Hui-Mei Lin; Yu-Sheng Chao; Andrew Yueh
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

9.  Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence.

Authors:  M Bray; R Men; I Tokimatsu; C J Lai
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

10.  Molecular mechanism of pathogenesis of dengue virus: Entry and fusion with target cell.

Authors:  S K Jain
Journal:  Indian J Clin Biochem       Date:  2005-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.